From Tuesday Generex Conference Call - 15 October 2019 (Page 2/28)

See: https://www.generex.com/

"So, we've decided to rights to offering with NuGenerex Immuno-Oncology to Generex's shareholders. The right to offer would be offered to our shareholders a very appealing and beneficial rate, with the proceeds to be used for operations, clinical trials, and immediately comply with the NASDAQ listing " - CEO GENEREX

Got it right? Will NGIO be listed on Nasdaq? If true, that's great news!

Thanks Generex TEAM!